ABSTRACT

KEYWORDS

REFERENCES

1. Stey C, Steurer J, Bachman S, Medici T, Tramer M. The effect of oral N-acetyl-cysteine in chronic bronchitis; a quantitative systematic review. Eur Respir J 2000; 16: 253-262.

2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Document 2006. NHLB/WHO Global initiative for chronic lung Disease. www.goldcopd.org

3. Celli BR, MacNee W, and Committee Members. Standards for diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946; 366:1875-1881.

4. Marerba M, Ponticiello A. Effect of twelve- months therapy with oral ambroxol in preventing exacerbation in patient with chronic obstructive pulmonary disease. (AMTHIST trial) Pulm Pharmacol Ther 2004; 17(1): 27-34.

5. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Datebase of Systematic Reviews 2006 Issue 3 art no. CD001287

6. Allegra LC. Prevention of acute exacerbation of chronic bronchitis with carbocysteine. Respiration 1996; 63: 174-80.

7. Poole PJ, Black PN. Oral mucolytics drugs for exacerbations of chronic obstructive pulmonary disease. BMJ 2001: 1271.

8. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, et al. Orally administer N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531-535.

9. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-357.

10. British Throracic Society research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airway obstruction. Thorax 1985; 40: 832-835.

11. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomized placebo-controlled trial. Lancet 2005; 365: 1552-1562.

12. Collet JP, Shapiro P, Ernst P, Renzi P, Ducruet T, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1719-1724.

13. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.

14. Hu G, Cassano PA. Antioxidant nutrients and pulmonary function; The Third National Health and Nutrition Examination Survey (NHANES III). Am J Epidemiol 2000; 151: 975-981.

15. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease: the National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139: 1435-1438.

16. VanItallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalized indices of the body´s fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr 1990; 52: 953-959.

17. Schols AM, Soeters PB, Dinggemans AMC, Mostert R, Frantzen PJ, Wouters EF. Prevalence characteristics of nutrional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.

18. Steiner AM, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 2002; 19: 626-631.

19. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: A meta-analysis. Chest 2000; 117: 672-678.

20. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 2003; 19: 120-127.

21. Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM. Effects of whole-body exercise training on body composition and functional capacity in normal-weigh patients with COPD. Chest 2004; 125: 2021-2028.

22. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390-1413.

23. Landbo C. Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.

24. ERS Consensus Statements. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.

25. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 77S-120S.

26. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 832-836.

27. Craven J, Sutherland A. Buspirone for anxiety disorders in patients with severe lung disease. Lancet 1991; 338: 249.

28. Singh NP, Despars JA, Stanbury DW, Avalos K, Light RW. Effects of buspirone on anxiety levels and exercise tolerance in patients with mild chronic obstructive pulmonary disease. Chest 1993; 103: 800-804.

29. Strom K, Boman G, Pehrsson K, Alton M, Singer J, et al. Effect of portriptyline, 10 mg daily on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J 1995; 8: 425-429.

30. Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998; 39: 24-29.

31. Eiser N, Harte R, Karvounis S, Phillips C, Isaacs M. Effect of treatment of depression in patients with COPD. Am J Respir Crit Care Med 1998; 157: A785.